Fresno, CA (PRWEB) March 30, 2012
HemaClear, the world leader in sterile, disposable tourniquet technology, announced today that HemaClear Tourniquets were the focus of a study conducted by Dr. Eric D. Ladenheim, President of the Ladenheim Dialysis Access Centers in Fresno, California. The study showed that sterile, disposable tourniquets were successfully used in forearm access dialysis surgery performed on 27 patients. This study was the first to illustrate the benefits of Hemaclear tourniquets beyond the growing demand in orthopedic surgery.
Dr. Ladenheim presented the study at the American Society of Diagnostic and Interventional Nephrology medical conference held in New Orleans on February 25, 2012.
The presentation highlighted how sterile, disposable tourniquets provide near-perfect exsanguination, excellent exposure, improved visibility, and elimination of direct placement of blocking tools on blood vessels. Dr. Ladenheim concluded his presentation by saying that HemaClear is effective and safe in facilitating bleeding free upper extremity hemodialysis vascular procedures, and in particular in eliminating the need for blood transfusion in these procedures.
“The main advantage [of using HemaClear in these procedures] is the prevention of blood loss in cases where upper arm procedures would have otherwise sustained substantial bleeding and need of blood transfusion”, Dr. Ladenheim noted in his presentation of the study, and added that “No transfusion was required in this group”.
"Although we had originally developed sterile, disposable tourniquet technology for application in orthopedic surgery, we knew the medical community would expand its use into related specialties.” Said Mr. Oren Gavriely, CEO of HemaClear, and added, ”this study is an excellent example of how HemaClear tourniquet technology not only provides more effective exsanguination than pneumatic tourniquets, but actually improves the quality of care patients receive and increases the likelihood of qualifying for a kidney transplant."
HemaClear® is the original developer of sterile, disposable tourniquet technology that exsanguinates, occludes, and provides a clear surgical field. The technology not only reduces blood loss, infection, and the volume of ischemic tissue, its simplicity saves as much as fifteen minutes of critical OR set-up time‚ eliminating over 100 separate steps that can add as much as $300 to every procedure.
In fact, HemaClear is so revolutionary, it represents the single greatest advance in tourniquet technology since the Esmarch bandage. HemaClear® has been proven successful and medically safe worldwide in over 300,000 surgical cases, both in the OR and in the field, including disaster-struck areas across the world.
Founded in 1999, HemaClear is based in Haifa, Israel, with offices in 30 countries covering over 2000 operating rooms. For more information about HemaClear, visit http://www.hemaclear.com
Ladenheim Dialysis Access Centers (LDAC) is a multicenter practice that specializes in all aspects of managing access for dialysis for Central California.
New technologies and developments are part of LDAC. We have an active Research program that works with Physicians, nurses, and scientists around the world looking for new ways to assist with promoting long term life of your Dialysis Access. For more information about LDAC please visit us at http://www.ladenheim.net